Thomas Weisel Partners

The Cannabist Company Announces Leadership Transition

Retrieved on: 
Monday, January 15, 2024
Natural Resources, Alternative Medicine, General Health, Health, Specialty, Food, Beverage, Cannabis, Retail, Entrepreneurship, Family, Thomas Weisel Partners, Duff, Patient, Duff & Phelps, Professional, Research, Heart, Partner, Investment, Y Combinator, Microsoft, History, Business, MBA, Duke University, Hospital, Auburn University, Columbia University, Mergers and acquisitions, NEO, Vita, Marketing, Intel, Certification, Management

“We all owe Nick a debt of gratitude for having the vision to form what is now The Cannabist Company more than a decade ago.

Key Points: 
  • “We all owe Nick a debt of gratitude for having the vision to form what is now The Cannabist Company more than a decade ago.
  • We are excited for what lies ahead and eager to continue the progress as The Cannabist Company evolves, from continuing to strengthen the balance sheet to expanding our wholesale program and driving organic growth,” said David Hart, Chief Executive Officer of The Cannabist Company.
  • Vita co-founded The Cannabist Company, formerly Columbia Care, in 2012 when he became the Company’s first employee.
  • “The Cannabist Company would not exist as it does today without Nick and his fortitude to lead us through the peaks and valleys of running a cannabis company.

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Pharmaceutical, Health, Biology, Multimedia, Business, Star, Acquisition, Eli Lilly, Business administration, Merrill (company), MBA, Doctor of Philosophy, Therapy, Pioneer Hi Bred International, University, Growth, Patient, Triple accreditation, Thomas Weisel Partners

Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.

Key Points: 
  • Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.
  • Mr. Robertson brings more than twenty years of experience with corporate strategy, business operations, capital raising and M&A.
  • View the full release here: https://www.businesswire.com/news/home/20240103822562/en/
    Star CFO-CBO Scott Robertson (Photo: Business Wire)
    “We are excited to welcome Scott to the Star leadership team during this time of significant growth,” said Adam Rosenthal, PhD, Chief Executive Officer and Founder of Star Therapeutics.
  • “I’m very excited to join the Star Therapeutics team at a time of great momentum with its proven approach for translating novel biology into first-in-class antibody therapies.

Cantor Fitzgerald Bolsters Technology Vertical with Two Senior Hires in Investment Banking and Research

Retrieved on: 
Wednesday, December 13, 2023
Georgetown University, Research, Thomas Weisel Partners, Senior, Columbia Business School, Cole, Evercore, Morgan Stanley, Stifel, Lehman Brothers, Princeton University, Mergers and acquisitions, Semiconductor, MBA, Cantor Fitzgerald, Investment banking, Research fellow, Business, Barclays, Knowledge, Mergers & Acquisitions, Management, Security (finance), Cantor

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Cantor Fitzgerald, L.P. ("Cantor"), a leading global financial services firm, today announced the appointments of Cole Bader as Global Head of Technology Investment Banking and C.J. Muse as Senior Managing Director, Semiconductor Analyst. These appointments mark a significant expansion for Cantor in the technology space. Mr. Bader will report directly to Sage Kelly, Global Head of Investment Banking. Mr. Muse will report directly to David Siffringer, Global Head of Equity Research.

Key Points: 
  • Muse joins as Senior Managing Director, Semiconductor Research Analyst
    NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Cantor Fitzgerald, L.P. ("Cantor"), a leading global financial services firm, today announced the appointments of Cole Bader as Global Head of Technology Investment Banking and C.J.
  • Mr. Bader will report directly to Sage Kelly, Global Head of Investment Banking.
  • Sage Kelly, Senior Managing Director and Global Head of Investment Banking, commented on today's announcement, "Cole's extensive experience and proven leadership in the technology investment banking space will strengthen our capabilities and deliver enhanced value to our clients.
  • Mr. Bader's arrival at Cantor is part of a broader initiative, bringing together over 30 technology investment banking professionals to Cantor to develop a newly active industry vertical with a diverse product offering.

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Retrieved on: 
Monday, October 23, 2023
Apolipoprotein, Nomura Securities, Morgan Stanley, Neuroscience, NAMS, BMO Capital Markets, Biotechnology, CETP, Head, Research, Thomas Weisel Partners, The Wall Street Journal, Wall Street, Health, CFO, Therapy, Patient, Dyslipidemia, Cardiovascular disease, Prudential Securities, Pharmaceutical industry, Biology, New York University

Mr. Somaiya is an established healthcare executive with extensive financial and operational expertise, including over two decades of experience on Wall Street as a prominent biotechnology research analyst.

Key Points: 
  • Mr. Somaiya is an established healthcare executive with extensive financial and operational expertise, including over two decades of experience on Wall Street as a prominent biotechnology research analyst.
  • Ian is a proven leader, who possesses a breadth of industry experience, as well as deep relationships within the financial community,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
  • We look forward to his many contributions.”
    Mr. Somaiya joins NewAmsterdam Pharma with over twenty-five years’ experience in senior leadership roles in the biopharmaceutical industry.
  • Prior to joining TCR2, Mr. Somaiya was managing director and head of biotechnology research at BMO Capital Markets.

PRIMO WATER CORPORATION ANNOUNCES APPOINTMENT OF DAVID HASS AS CHIEF FINANCIAL OFFICER

Retrieved on: 
Tuesday, January 24, 2023
Client, Water, Accenture, Thomas Weisel Partners, CFO, Drinking water, NYSE, GM, TSX, FP, Retirement, Finance, Management, Stifel, Strategy

TAMPA, Fla, Jan. 24, 2023 /PRNewswire/ - Primo Water Corporation (NYSE: PRMW) (TSX: PRMW) (the "Company" or "Primo"), a leading provider of sustainable drinking water solutions in North America and Europe, today announced the appointment of David W. Hass as Chief Financial Officer.

Key Points: 
  • TAMPA, Fla, Jan. 24, 2023 /PRNewswire/ - Primo Water Corporation (NYSE: PRMW) (TSX: PRMW) (the "Company" or "Primo"), a leading provider of sustainable drinking water solutions in North America and Europe, today announced the appointment of David W. Hass as Chief Financial Officer.
  • Mr. Hass is replacing Mr. Jay Wells, who previously announced his planned retirement as Chief Financial Officer, effective April 1, 2023.
  • "David is a strategic and purpose-driven leader with an exceptional depth of experience across our business," said Tom Harrington, Chief Executive Officer of Primo. "
  • From 2011 to 2020, Mr. Hass served in various roles with legacy Primo, including Chief Strategy Officer, Vice President of Strategy, Vice President of Financial Planning & Analysis (FP&A), as well as GM of the Canadian Business Unit and the Water Direct Business Unit.

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Retrieved on: 
Tuesday, December 13, 2022
Head, Quality of life, Annual report, Private, VTV, Pancreatic cancer, FDA, Business, Kidney, Food, Thomas Weisel Partners, T1D, Deutsche Bank, BMO Capital Markets, Consumer, IPO, Diabetes, Cystic fibrosis, University, Patient, Chronic obstructive pulmonary disease, BMO, MBA, Investment, Corporation, Therapy, Risk, PIPES, Corporate development, BBA, Pharmaceutical industry, Stifel

HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately.

Key Points: 
  • HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately.
  • On behalf of our board and executive team, I welcome Steven to vTv.”
    Mr. Tuch has had a distinguished career with more than 20 years of financial and business development experience with multiple life science companies through various stages of financial planning and development.
  • Prior to joining vTv, he served as Head of Corporate Development at Rallybio Corporation, leading the Company through its $92.7 million IPO in July 2021.
  • Mr. Tuch earned an MBA from Stanford University’s Graduate School of Business and a BBA from the University of Michigan.

DAVID V. HEDLEY III JOINS SANMINA'S BOARD OF DIRECTORS

Retrieved on: 
Thursday, December 8, 2022
Sola, Partner, Wall Street, Canaccord Genuity, Morristown–Beard School, Ernst, Electronics manufacturing services, Flex (company), GLAAD, Hedley, Original equipment manufacturer, SANM, Colgate University, Trustee, UBS, Strategic planning, Advisory board, EMS, Senior, BA, Originality, Merrill (company), SAN, Thomas Weisel Partners, Management, Sanmina Corporation

SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Sanmina Corporation ("Sanmina" or the "Company") (NASDAQ: SANM), a leading integrated manufacturing solutions company, today announced the appointment of David V. Hedley III to the Company's Board of Directors, effective December 5, 2022.

Key Points: 
  • SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Sanmina Corporation ("Sanmina" or the "Company") (NASDAQ: SANM), a leading integrated manufacturing solutions company, today announced the appointment of David V. Hedley III to the Company's Board of Directors, effective December 5, 2022.
  • Hedley has 30 years of Wall Street experience as an investment banker with a focus on the technology sector.
  • Hedley is responsible for leading strategic initiatives, developing the corporate vision, and managing strategic planning.
  • "We are pleased to welcome David to Sanmina's Board," said Jure Sola, Chairman and Chief Executive Officer of Sanmina.

LifeSci Advisors Expands Digital Health Team with Appointment of Caroline Paul

Retrieved on: 
Thursday, December 1, 2022
Organizational founder, Digital, Vanderbilt University, San Francisco, Silicon, Wall Street, Initial public offering, Corporation, Lazard, Thomas Weisel Partners, IPO, Partnership, Information technology, B.A, Health, Research, Edwards Lifesciences, Barclays, Pharmaceutical industry

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Advisors , an investor relations and corporate communications firm focused on the healthcare sector, today announced the continued expansion of its digital health practice with the appointment of Caroline Paul as Managing Director.

Key Points: 
  • NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Advisors , an investor relations and corporate communications firm focused on the healthcare sector, today announced the continued expansion of its digital health practice with the appointment of Caroline Paul as Managing Director.
  • Carolines background is a perfect fit for our growing digital health franchise, as we continue to add new clients in the sector, said Mike Rice, Cofounder of LifeSci Advisors.
  • Digital health is becoming an important component of the U.S. and global healthcare ecosystems, driven by investment in information technology.
  • Ms. Paul commented, I am thrilled to be joining LifeSci's team to focus on digital health alongside Steve Halper.

Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires

Retrieved on: 
Wednesday, November 16, 2022
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University of California, San Francisco, Sale, AD, Deutsche Bank, Stanford Graduate School of Business, Merck, Atopic dermatitis, Equity, Economics, Cholestatic pruritus, Biochemistry, CFO, Therapy, Alma College, OSI Pharmaceuticals, Los Alamos National Laboratory, Purdue University, Huron, CMC, MRGPRX4, DePaul University, Chemistry, CSU, San Francisco, Quality control, Ohio State University, Growth, MBA, Corporation, Cholestasis, Drug discovery, UCB, Biomedical engineering, Research, University, MRGPRX2, Business, Thomas Weisel Partners, Business development, Doctor of Pharmacy, BioMarin Pharmaceutical, Operational definition, Sanofi, Pharmaceutical industry, Management, Bayer

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team.
  • We are pleased to welcome Aaron, David, and Greg to Escient Pharmaceuticals said CEO Joshua Grass.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.
  • Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.

Macquarie Capital Names Greg Ager Managing Director in Software and Services Group

Retrieved on: 
Tuesday, November 8, 2022
Banking, Professional Services, Finance, Morgan Stanley, Wachovia Securities, Acquisition, Payit, Capital, Macquarie Group, Information services, Growth, Providence Equity, Signal Hill, Cornerstone, Faculty, Knowledge, Interfolio, Software as a service, Cornerstone OnDemand, Vista Equity Partners, Macquarie, Education, View, Health, Educational technology, Telecommunication, ERP, Solution, Thomas Weisel Partners, Sale, Technology, CEO, Financial services, Security (finance), Software, Elsevier, Altacast

Macquarie Capital, the corporate advisory, capital markets and principal investing arm of Macquarie Group, today announced that it has appointed Greg Ager as Managing Director in its Software and Services group.

Key Points: 
  • Macquarie Capital, the corporate advisory, capital markets and principal investing arm of Macquarie Group, today announced that it has appointed Greg Ager as Managing Director in its Software and Services group.
  • Mr. Ager will report to Sam Shah, Co-Head of Macquarie Capital in the Americas and Global Head of Software and Services.
  • Macquarie Capitals Software and Services group serves companies specializing in professional services, information services, supply chain management, education, telecoms, networks and digital infrastructure.
  • Macquarie Capital is the advisory, capital markets and principal investment arm of Macquarie Group.